Edition:
India

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

18.67USD
22 Jun 2018
Change (% chg)

$0.22 (+1.19%)
Prev Close
$18.45
Open
$18.57
Day's High
$19.06
Day's Low
$18.30
Volume
403,112
Avg. Vol
361,472
52-wk High
$27.07
52-wk Low
$8.36

Chart for

About

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The... (more)

Overall

Beta: 3.62
Market Cap(Mil.): $1,019.17
Shares Outstanding(Mil.): 47.45
Dividend: --
Yield (%): --

Financials

BRIEF-FDA Grants Breakthrough Therapy Designation To Omeros' Masp-2 Inhibitor Oms721

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO OMEROS’ MASP-2 INHIBITOR OMS721 FOR THE TREATMENT OF HIGH-RISK HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

27 Apr 2018

BRIEF-Omeros Announces Amendment Of Credit Facility

* AMENDED ITS EXISTING CREDIT FACILITY WITH CERTAIN AFFILIATES OF CRG LP

11 Apr 2018

BRIEF-Omeros Q4 Loss Per Share $0.34

* Q4 REVENUE $13.8 MILLION Source text for Eikon: Further company coverage:

02 Mar 2018

BRIEF-European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721

* EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY

22 Jan 2018

BRIEF-Omeros Reaches Agreement With FDA On OMS721 Phase 3 Trial Protocol For IgA Nephropathy

* OMEROS CORPORATION REACHES AGREEMENT WITH FDA ON OMS721 PHASE 3 TRIAL PROTOCOL FOR IGA NEPHROPATHY

03 Jan 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.84 +1.39
Novartis AG (NOVN.S) CHF75.60 +0.10
Pfizer Inc. (PFE.N) $36.51 +0.21
Roche Holding Ltd. (ROG.S) CHF216.45 --
Roche Holding Ltd. (RO.S) CHF223.60 +4.00
Merck & Co., Inc. (MRK.N) $61.47 +0.29
Bayer AG (BAYGn.DE) €98.84 +2.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €69.01 +1.30
Eli Lilly And Co (LLY.N) $85.92 -0.15

Earnings vs. Estimates